Taking stock of the drug industry, from the lab to the medicine chestMarch 8, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Markus Wilborn for STAT HHS secretary signals support for new restriction on addiction treatment Some addiction experts criticize a DEA proposal limiting access to buprenorphine; Xavier Becerra said it balanced safety and patient needs. By Lev Facher FDA issues rare comment on approval of Covid and flu home test from company that went bankrupt The new details could be a sign that the FDA is becoming more flexible about its requirements for approving at-home flu test kits. By Brittany Trang STAT+ | Many doctors spend their days battling insurers. Why do some go to work for 'the dark side'? The prior authorization process draws ire from many physicians. But some wind up leaving clinical medicine to work for "the dark side." By Trisha Pasricha Markus Wilborn for STAT Becerra: Judge set to rule on abortion pill is 'beginning to read the law' "Everyone thought by now we would have a ruling from that judge," Becerra said. "My suspicion is he's beginning to read the law." By Lev Facher Opinion: How cross-state licensure reform can ease America's mental health crisis The antiquated system of licensure in the U.S. is creating a huge barrier to realizing the potential of telehealth for mental health care. By Harry Ritter More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments